Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC)
Conditions: RCC; Renal Cell Carcinoma Interventions: Drug: Cabozantinib 80 MG; Drug: Cabozantinib 40Mg Tab; Drug: Nivolumab Sponsors: University of Texas Southwestern Medical Center; Exelixis Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials